Codex @codex  0

An experience of a voice without an ordinary corresponding external speaker. Location, frequency, content, control, interpretation and distress are separable dimensions; the experience is not specific to schizophrenia.

Primary multi-stage GWAS. Formal group author is the Schizophrenia Working Group of the Psychiatric Genomics Consortium; loci and associations are not interchangeable with genes.

Original subtitle: a population-based study. Published title differs from the accessible manuscript title Common genetic influences for schizophrenia and bipolar disorder: A population-based study of 2 million nuclear families; DOI and author identity agree.

Auditory verbal hallucinations are associated with psychotic disorders but are neither sufficient for schizophrenia nor confined to people with a mental disorder. Their clinical significance depends on the wider pattern of experience, distress, functioning, context and risk. The distinction between an association and a diagnostic implication is essential: a high probability of voice hearing among people with a diagnosis does not establish the same probability of that diagnosis among all people who hear voices.

An auditory verbal hallucination is an experience of a voice without an ordinary corresponding external speaker. That phenomenological description does not specify its cause, the person's interpretation or a need for care. Psychosis is a broader clinical description involving disturbances such as hallucinations, delusional conviction or disorganization; schizophrenia requires a pattern assessed over time and in context. A single perceptual experience should therefore not be treated as a miniature diagnosis. Equally, locating an experience outside a diagnostic category does not mean that distress or support needs are unreal.

Population research illustrates the importance of context and definition. Maurice M. Ohayon's surveys of 13,057 people in three European countries distinguished experiences around falling asleep or waking from daytime hallucinations. Sleep-transition experiences were often not associated with a specific pathology, whereas daytime auditory and visual hallucinations showed stronger associations with psychiatric conditions. Thus a broad prevalence of unusual perception cannot be quoted as the prevalence of persistent daytime voice hearing, and the existence of nonpathological experiences cannot justify ignoring the risk associations of other presentations.^[ref]

More directly, Kirstin Daalman and colleagues compared 118 clinical and 111 otherwise healthy people who reported recurrent auditory verbal hallucinations. Perceived location, number, loudness and personification did not reliably separate the groups, whereas emotional valence of the content, frequency and perceived control differed more strongly. The comparison is important because nonclinical participants had recurrent experiences, not only a one-off event around sleep. It undermines a simple rule that an externally located or vivid voice establishes psychotic disorder.^[ref]

The findings do not mean that the groups are identical. Negative content, distress and reduced control can be clinically important even if loudness is shared. Selection also matters: volunteers willing to identify as healthy voice-hearers may have unusual coping resources or interpretations. A cross-sectional contrast cannot show that every currently nonclinical participant will remain well, nor that one dimension has the same predictive value in an unselected population. The in-sample classification performance of a feature should not be treated as a validated universal diagnostic test.

Emmanuelle Peters and colleagues compared people with persistent psychotic experiences without a need for care, clinical participants and controls. The nonclinical group could report marked unusual experiences while differing from the clinical group in functioning, emotional problems, appraisals and social circumstances. Childhood trauma occurred in both experience groups, so its presence did not uniquely identify clinical status. This supports examining protective factors and the consequences of an experience alongside its occurrence. It does not establish that one protective factor causally prevents illness.^[ref]

An appraisal account proposes that the meaning assigned to an experience helps determine distress and action. A voice interpreted as an omnipotent persecutor may have different consequences from an equally vivid experience understood as manageable. That difference should not be reduced to whether an explanation is simply “internal” or “external”: personal threat, perceived power, control and context may be more informative. Nor should culturally meaningful explanations automatically be classed as delusions merely because they differ from a clinician's expectations.

Emmanuelle Peters and colleagues extended the comparison with experimental anomalous-experience tasks. These included computer-based apparent thought interference and manipulated headphone sounds, followed by appraisal measures. Clinical participants made more threatening interpretations than the nonclinical experience group, which was closer to controls on these tasks. Presenting comparable events strengthens the argument that interpretation contributes beyond naturally different experiences. However, the groups were not randomly assigned clinical status and the tasks were analogues; the study does not prove that appraisal alone caused later illness.^[ref]

Biological observations do not restore a one-to-one diagnostic mapping. Kelly M. J. Diederen and colleagues used symptom-capture functional magnetic resonance imaging while clinical and nonclinical participants indicated voice episodes by squeezing and releasing a balloon. The study found substantial similarities in hallucination-associated activity. A process can therefore have a neural correlate without being specific to a disorder. The result also does not prove identical neural codes or show that every causal pathway to voice hearing is the same; imaging resolution, sample size and comparison conditions constrain the conclusion.^[ref]

This distinction between experience and disorder has two-sided implications. Defining all voice hearing as disease risks pathologizing people who function well and do not want clinical treatment, while defining it as always harmless could obscure severe distress or other problems. Need for care should be evaluated through the person's difficulties, circumstances and preferences, with appropriate attention to risk and other causes. Actual service contact is an imperfect measure because access, discrimination and willingness to seek help affect who receives a diagnosis.

A stronger evidence base would follow representative voice-hearers over time, measure multiple dimensions separately and record changes in functioning as well as diagnostic outcomes. It would test whether appraisal predicts later distress beyond baseline severity and whether changing a proposed process improves meaningful outcomes. Cultural comparison also requires equivalent questions rather than assuming that the same word for a voice has the same interpretation everywhere. These designs could distinguish a broad continuum of experience from the more specific processes that lead to disabling difficulties.

Voice hearing is transdiagnostic and can be nonclinical; its association with schizophrenia is a conditional relationship, not an identity. The appropriate scientific task is to explain which dimensions, contexts and interacting processes make an experience distressing or disabling. This retains the value of diagnostic assessment while avoiding the inference that one unusual experience determines a person's mental health or humanity.

Goffman's claim is illuminating as an account of how stigma can deny full personhood, but it should not be treated as a literal universal belief held by everyone who encounters a psychosis diagnosis. Evidence supports stereotyping, social exclusion and failures to recognize agency; these are related to, but not identical with, measured dehumanization. The important implications concern how labels change relationships, expectations and opportunities, alongside the genuine benefits that assessment and diagnosis can provide.

In Erving Goffman's analysis, stigma is relational: an attributed characteristic becomes discrediting within a particular social setting. Reducing a person to a marked identity can make their other qualities, perspective and ordinary claims to participation seem less important. The quoted passage captures this moral reduction. It is not a definition that people with psychosis are less human, nor empirical proof that every diagnostic interaction has that effect. A scientific evaluation must specify which response is being measured and avoid turning a critique of prejudice into a description of the person targeted.^[ref]

Several constructs need separation. A stereotype attributes characteristics to a group; prejudice evaluates its members; discrimination changes their treatment. Dehumanization more specifically withholds qualities or standing ordinarily granted to persons, such as agency, emotional depth or equal moral consideration. Social distance measures willingness to interact and is an indicator of exclusionary attitudes, not a direct assay of whether someone is literally regarded as human. The distinction matters because evidence for one construct cannot automatically be cited as decisive proof of all the others.

Bernice A. Pescosolido and colleagues compared public responses to diagnostic vignettes in the 1996 and 2006 General Social Surveys. Biological understandings and treatment endorsement increased, but stigma indicators did not show corresponding improvement. For schizophrenia, substantial unwillingness to engage in several ordinary relationships persisted. This challenges the assumption that greater recognition of a biological condition automatically dissolves social exclusion. Repeated population surveys describe change and associations; they cannot isolate the causal effect of a public campaign or a biological explanation from all concurrent social changes.^[ref]

The implication is not that biological knowledge is intrinsically stigmatizing. A biological explanation can reduce moral blame yet be heard as evidence of permanent difference or incapacity. Whether it emphasizes change, individual variation and retained agency therefore matters. Treating a person as a malfunctioning mechanism can support mechanistic dehumanization, while a well-explained biological contribution can coexist with a respectful psychological and social account. The relevant empirical question concerns the framing and consequences of an explanation, rather than whether biology or psychology is the morally acceptable level of science.

Matthew S. Lebowitz and colleagues experimentally varied biological and psychosocial explanations in descriptions assessed by mental-health clinicians. Biological explanations reduced reported empathy in the tested conditions. Random allocation strengthens a causal conclusion about the immediate effect of the explanatory framing on that outcome. It does not establish that biological treatment causes poor care, that all clinicians respond alike, or that dehumanization was uniquely the mediator. Self-reported empathy is also different from observing the quality of an actual clinical encounter.^[ref]

Evidence from people receiving diagnoses is especially important because exclusion is not exhausted by public opinions. Graham Thornicroft and colleagues interviewed 732 people with schizophrenia in 27 countries about experienced and anticipated discrimination. Reports concerned relationships, work and other ordinary domains; many participants also anticipated exclusion and felt a need to conceal their diagnosis. The study establishes the breadth of reported disadvantage and distinguishes anticipation from experience. As a service-based cross-sectional survey, it does not estimate every country's population prevalence or isolate the diagnostic label from symptoms, poverty and other causes of disadvantage.^[ref]

Anticipation can itself restrict opportunities even before a particular rejection occurs. Concealment may protect against a real threat while making support harder to obtain. Self-stigma can arise if a public stereotype is accepted as a judgment about one's own worth or capacity. These processes offer plausible routes from social attitudes to reduced participation, but an individual's withdrawal should not automatically be attributed to faulty beliefs: discrimination can be an accurate expectation. A formulation that ignores structural constraints risks blaming the person for adapting to an exclusionary environment.

The implications for care include listening to the person's account, distinguishing symptoms from capacities, and explaining assessment without treating a label as a complete identity. Diagnostic overshadowing is a particular risk when an existing psychiatric label substitutes for examining a separate complaint. These are testable practice concerns, not conclusions that every clinician commits those errors. A diagnosis can also validate distress, enable access to effective support and provide a shared vocabulary. Evaluating labeling therefore requires comparing both benefits and harms instead of assuming that abandoning all diagnostic language would remove stigma.

Intervention evidence gives a reason to reject inevitability. Sarah Clement and colleagues randomized 216 student nurses to filmed social contact, live contact or a lecture. The contact conditions involved accounts from service users and carers; combined contact conditions improved some attitude and intended-behavior measures relative to the lecture, with the intended-behavior difference maintained at four months. The study supports contact-based approaches beyond simply adding factual information. Its self-reported outcomes and selected professional-training setting limit claims about actual discrimination or all public contexts.^[ref]

An intervention should consequently be judged on consequential treatment and participation as well as knowledge scores. Service-user involvement can preserve individuality and agency, but it must avoid presenting one unusually successful person as an exception who leaves the broader stereotype untouched. Organizational policies, accountability and access to work or housing may matter even when personal attitudes improve. Conversely, institutional rules alone may leave everyday interactions hostile. These are complementary levels for evaluation rather than alternatives to a clinical understanding of psychosis.

The evidence supports Goffman's warning about the reduction of personhood, while opposing a deterministic reading of it. Psychosis diagnoses can attract serious exclusion, yet the form and strength of that response vary and can be changed. A humane and scientifically adequate response combines effective care with recognition of agency, individual variation and equal social standing, measuring whether those commitments alter people's actual opportunities.

Converging family, twin, adoption and molecular evidence establishes genetic contributions to vulnerability to several mental disorders; it does not make onset inevitable or identify a single genetic cause for every diagnosis. The outcome must be specified. Genetic influences on lifetime diagnostic liability are not automatically the same as influences on the exact age of first onset, episode recurrence, symptom severity or treatment response.

Family aggregation provides a starting point. Relatives of affected individuals can have higher rates of the same disorder, with closer biological relatives generally showing greater risk. However, families share environments, social circumstances and diagnostic expectations as well as genes. A familial association alone therefore cannot distinguish genetic transmission from environmental transmission or their combination. Designs exploiting differences in genetic relatedness and rearing relationships address this ambiguity more directly.

In a twin study, monozygotic twins share essentially all inherited sequence variation, whereas dizygotic twins share about half of segregating additive variation on average. Greater resemblance among monozygotic pairs supports a genetic contribution if relevant environmental similarity and ascertainment assumptions are adequately addressed. Under a simple standardized ACE model, the twin correlations satisfy $r_{\mathrm{MZ}}=A+C$ and $r_{\mathrm{DZ}}=A/2+C$, giving $A=2(r_{\mathrm{MZ}}-r_{\mathrm{DZ}})$. For diagnoses, investigators commonly model an underlying liability-threshold model, rather than treating crude concordance percentages as continuous-trait correlations. Patrick F. Sullivan and colleagues' meta-analysis of 12 systematically ascertained schizophrenia twin studies estimated substantial heritability of liability, around $81\%$. That is a model-based population estimate with uncertainty, not an individual's probability of developing schizophrenia.^[ref]

Twin comparisons have limitations. Monozygotic twins may be treated more similarly, prenatal environments can differ systematically, and the equal-environments assumption concerns environments causally relevant to the disorder rather than identical treatment in every respect. Assortative mating alters expected resemblance, while nonadditive effects and measurement error complicate variance decomposition. Monozygotic concordance below one is incompatible with a simple fully penetrant deterministic account, but the difference cannot be assigned wholly to one specific environmental exposure: stochastic development, diagnostic error and other processes also contribute.

Adoption and extended-family data provide a partly independent test. Paul Lichtenstein and colleagues linked Swedish population and psychiatric inpatient registers, studying over two million nuclear families. They compared biological and adoptive relationships, full siblings and half-siblings for schizophrenia and bipolar disorder. Risk patterns followed biological relatedness, and adopted children of biological parents with bipolar disorder also showed elevated schizophrenia risk. The analysis supported partially shared genetic influences across the two diagnoses. This weakens an explanation based solely on living with an affected biological parent.^[ref]

It does not eliminate every environmental explanation. Selective placement, prenatal exposure, contact with biological relatives and nonrandom adoption can matter. Inpatient-register diagnoses preferentially identify people reaching those services, and changing diagnostic practice can affect estimates. Nevertheless, convergence across twins, extended families and adoption is more persuasive than repeating one family association, because the sources of confounding differ.

Molecular evidence measures inherited variation directly. In a genome-wide association study, genotype frequencies are compared between cases and controls across many markers, using stringent multiple-testing correction and replication. The Psychiatric Genomics Consortium's 2014 schizophrenia study analyzed up to 36,989 cases and 113,075 controls and identified 108 associated loci. The pattern supported a polygenic trait architecture involving many common variants, individually having small effects, rather than one common “schizophrenia gene.” Genotypes precede clinical onset, so the inherited sequence difference is not created by experiencing the disorder.^[ref]

However, an associated marker may tag a causal variant through linkage disequilibrium; a locus is neither necessarily one gene nor a fully identified biological mechanism. Population stratification, sample overlap and diagnostic heterogeneity can bias findings. A weighted genetic risk score can predict differences in risk in independent samples without providing accurate individual diagnosis or transferring equally across ancestry groups. Discovery of association is consequently stronger evidence for inherited liability than for the timing of a particular person's first episode.

The history of candidate gene research illustrates why replication matters. Richard Border and colleagues tested widely studied depression candidate-gene and gene-by-environment hypotheses across large samples with preregistered analyses. They found no convincing support for the historically proposed large effects. This does not erase genetic influences on depression or rule out every genotype-environment interaction; it challenges specific small-study claims and demonstrates why biological plausibility alone cannot validate an association.^[ref]

Finally, heritability is conditional on a population, environment and measurement system. A highly heritable vulnerability can still be preventable, and a low-heritability outcome can still involve essential biological mechanisms. Gene-environment correlation means inherited characteristics can influence the environments people encounter; genotype-environment interaction means their consequences can depend on those environments. Neither should be collapsed into an exclusive genes-versus-environment choice. The evidence strongly supports inherited differences in liability to several disorders, especially where family designs and replicated molecular findings converge; explaining actual onset additionally requires developmental and environmental evidence.

Aberrant salience is a useful account of how some psychotic experiences become compelling, but it is a hypothesis about a process contributing to symptoms, not a complete explanation of schizophrenia. Salience concerns what captures attention and motivates interpretation or action. It is distinct from whether a stimulus is physically intense, pleasurable or objectively informative.

In Shitij Kapur's original framework, dysregulated dopamine gives inappropriate motivational significance to ordinary events or internally generated representations. A coincidental glance can consequently feel urgent and personally directed. A delusion may then be an attempt to explain that experience using the person's existing beliefs and circumstances. The model connects neurobiology with the subjective onset of psychosis rather than treating an unusual belief as a direct chemical readout. It also predicts that dampening salience can reduce the compelling quality of experiences before their interpretation has been revised. This is a theoretical synthesis, not an experiment proving the entire causal chain.^[ref]

The framework makes two separable predictions: inappropriate significance should attach to uninformative cues, and relevant cues may fail to gain appropriate significance. They should be measured independently. In the Salience Attribution Test used by Jonathan P. Roiser and colleagues, visual cues varied along colour and form dimensions, with only one dimension predicting monetary reinforcement. Reaction-time speeding and explicit probability ratings indexed responding to relevant versus irrelevant features. Patients showed reduced adaptive salience; importantly, the diagnostic groups did not differ overall in aberrant salience. Greater explicit aberrant salience occurred in patients with delusions relative to patients without them. The small, predominantly medicated sample, subgroup analysis and multiple comparisons prevent presenting this as a universal schizophrenia deficit.^[ref]

A useful measurement caution follows directly. If equally uninformative features receive noisy ratings $R_1,R_2$, the absolute difference $|R_1-R_2|$ is generally positive even when both estimates are unbiased. For independent normal errors of variance ${\sigma }^2$, its expectation is $2\sigma /\sqrt{\pi }$. A high score can therefore reflect rating noise or poor probability discrimination as well as genuinely assigned significance. Repeated trials, reliability assessment, explicit task comprehension and measurements of adaptive learning are needed to interpret the score.

Biological evidence is compatible with, but does not uniquely identify, the hypothesis. Oliver D. Howes and colleagues used fluorodopa PET to compare people with prodromal symptoms, patients with schizophrenia and controls. Elevated synthesis-related uptake in the associative striatum in the prodromal group links dopamine dysfunction to a stage before established psychotic illness. This was a case-control study; uptake is not a recording of cue-specific phasic dopamine, and a high-risk group does not establish that every individual will develop schizophrenia. It supplies an upstream biological constraint, not a demonstration that a particular neutral cue caused a delusion.^[ref]

Several explanatory steps remain. An account must specify why significance is assigned to this event, how a persistent interpretation is selected, and why contradictory evidence fails to revise it. Attention, memory retrieval, prior beliefs and the social environment can supply those constraints. Dopamine dysfunction need not explain all negative symptoms or cognitive difficulties. Antipsychotic effects cannot alone establish the original cause: altering a downstream component can improve symptoms arising through several pathways. Nor should a medication-associated decrease in ordinary motivation automatically be taken as recovery of selective salience.

A similar perspective is particularly productive for substance use disorder. Incentive salience distinguishes cue-triggered wanting from pleasure. Cindy L. Wyvell and colleagues separately trained a sucrose-seeking response and a reward-predictive cue. Accumbens amphetamine enhanced cue-triggered responding in a test without reward reinforcement, without enhancing sucrose liking measured by taste reactivity. A later sensitization experiment found amplified cue-triggered seeking in a drug-free test after prior exposure. The experiments distinguish motivation from hedonic impact; they do not themselves demonstrate every feature of human addiction.^[ref][ref]

This suggests how drug cues can capture behaviour even when enjoyment has declined or the person intends abstinence. Unlike psychosis, however, these cues were genuinely associated with reward. The shared issue is excessive or poorly regulated motivational control, not necessarily significance attached to statistically irrelevant events.

Anxiety disorders offer a second, more limited analogy: threat-related cues can monopolise attention, avoidance can maintain their significance, and safe cues may be treated as dangerous. In panic disorder, catastrophic interpretation can make ordinary bodily sensations feel threatening. Such accounts concern threat appraisal and discrimination and do not justify assuming identical dopamine abnormalities across diagnoses. Aberrant salience is most informative as a testable, transdiagnostic process whose computational meaning, neural implementation and clinical consequences must each be specified.

Learning and memory provide powerful mechanistic accounts of some psychiatric symptoms, but they are not an adequate single-level definition of all psychiatric disorders. The most useful claim is that abnormal learning, valuation or retrieval can mediate particular symptoms and interact with biological vulnerability and environment. Calling every persistent symptom a “memory” without specifying a computation, mechanism and discriminating prediction would make the account unfalsifiable.

Several causal positions must be separated. A learning abnormality could precede illness and increase vulnerability, mediate the expression of an established biological disturbance, or follow from the illness, medication or adverse experiences. A cross-sectional task deficit does not distinguish these possibilities. Nor does a diagnosis identify one latent parameter: poor performance can result from altered motivation, perception, attention, beliefs or motor output as well as learning. Construct validity and external validity are therefore central, not afterthoughts.

For schizophrenia, an influential proposal links dopamine dysregulation to aberrant salience. Events or internal representations acquire inappropriate significance, and attempts to explain those experiences can contribute to delusions. This creates a possible bridge between neurochemistry and acquired belief. It is a theoretical framework rather than evidence that each psychotic belief is an ordinary reinforced association; psychosis is also not specific to schizophrenia. The account must explain which symptoms it predicts and which remain outside its scope.^[ref]

A pharmacological experiment provides a more direct test of one link. Healthy volunteers performed causal associative learning during randomized ketamine and placebo sessions with functional magnetic resonance imaging. The drug perturbed right-frontal responses related to violated expectations, and individual neural responses were related to subsequently assessed perceptual and belief-like drug effects. This supports an association between altered learning-related processing and psychotomimetic experience. It does not show that ketamine reproduces the developmental course of schizophrenia, or that the observed imaging signal is the unique mediator of a delusion. Pharmacology causally changes the drug condition; the relationship between an imaging response and a symptom remains a separate inferential step.^[ref]

Prospective evidence helps with temporal ordering. Elevated striatal dopamine synthesis capacity was observed before transition to psychotic disorder in a high-risk cohort. That finding is important biological evidence, but a PET synthesis-capacity estimate does not directly measure trial-wise reward prediction errors, and elevated capacity does not establish a specific learning algorithm. It also does not imply that every high-risk person or every diagnosed patient has the same abnormality. A learning account should connect this biological vulnerability to task-defined computations rather than substitute one measure for another.^[ref]

For major depressive disorder, low expectations of control, persistent negative interpretations and reduced engagement with rewarding opportunities are plausible learning-related mechanisms. Learned helplessness provides a specific model of how uncontrollability can change later behaviour; attributional style helps explain generalization and persistence in human accounts. These mechanisms are neither a moral judgment about the individual nor proof that all adverse circumstances are controllable. Sleep, bodily symptoms, neurodevelopmental factors and the diversity of depressive presentations remain part of the explanandum.

Behavioural evidence is more precise than a global claim that depressed people “cannot learn.” In a probabilistic reward task, unmedicated depressed participants showed reduced development of response bias toward a more frequently rewarded stimulus, with analyses implicating integration of reinforcement history rather than total absence of response to an individual reward. This separates one aspect of reward learning from subjective pleasure and from every component of anhedonia. The direction of causation remains open in a cross-sectional comparison.^[ref]

Treatment findings can also link biological and cognitive levels. An acute norepinephrine-reuptake manipulation changed emotional processing in depressed participants before subjective mood changed. That observation is consistent with pharmacologically altered experience processing contributing to later improvement; it does not prove that the early task change mediates every later clinical response. Learning and pharmacology can interact rather than constitute mutually exclusive treatments. A drug might alter the conditions under which corrective experiences are encoded, while behavioural intervention supplies those experiences.^[ref]

The learning perspective generates concrete treatment hypotheses. In threat disorders, extinction learning suggests improving safety learning and its retrieval across contexts, rather than merely suppressing an immediate response. A randomized pilot study combined D-cycloserine or placebo with virtual-reality exposure to heights in people with acrophobia. Greater improvement in the adjunct condition provided an early proof of concept for facilitating a specified learning experience. The small, specific trial does not establish a general cognitive enhancer for all diagnoses, and an intervention that facilitates learning need not selectively strengthen desirable information. Treatment timing and the quality of the learning episode are therefore empirical issues.^[ref]

For psychotic symptoms, a learning account predicts that reducing inappropriate salience may permit new interpretation without instantly deleting established beliefs. For depression, it motivates tests of changes in reward sensitivity, information integration and expectations, with functional recovery as an outcome. These are treatment-development hypotheses, not conclusions that a single task parameter should dictate care. Symptom improvement, correction of a proposed mechanism and prevention of relapse require separate measurements; changing a laboratory score is not sufficient evidence of benefit.

The broad claim becomes convincing only when models predict specific patterns, survive controls for performance confounds, and show temporally appropriate changes linked to symptoms. Comparisons with unaffected high-risk individuals, longitudinal designs and mechanism-sensitive randomized trials can distinguish vulnerability, mediation and consequence. Learning and memory are therefore valuable explanatory levels and possible treatment targets, especially for particular acquired responses and beliefs. They do not replace the biological, developmental and social causes of psychiatric illness, and they should not turn diagnostic heterogeneity into one assumed defect.

Inherited variation contributes to psychiatric vulnerability and to some measured differences in adaptation after psychological stress, but its importance is phenotype-, population- and environment-dependent. Genetic influence is not equivalent to inevitability, a single large-effect gene or a wholly separate set of protective genes. A satisfactory answer must distinguish genetic effects on exposure, on symptoms and on responses conditional on exposure.

Family resemblance provides an initial clue, but families transmit environments and social circumstances as well as DNA. Twin comparisons exploit differences in relatedness: monozygotic pairs share essentially all inherited sequence variation, whereas dizygotic pairs share about half their segregating additive variation on average. Under an ACE model, greater resemblance of monozygotic pairs can support a genetic component if the relevant environmental and ascertainment assumptions hold. Equal environments means comparable effects of relevant environmental similarity, not literally identical treatment of every twin.

Disorder-level evidence is substantial. Patrick F. Sullivan and colleagues' ascertainment-aware synthesis of schizophrenia twin studies estimated liability heritability at roughly $81\%$, with uncertainty. Paul Lichtenstein and colleagues' Swedish family-register study supported partially shared inherited liability to schizophrenia and bipolar disorder using biological, adoptive and sibling relationships. The convergence supports inherited vulnerability while showing that diagnostic categories do not necessarily partition genetic causes into entirely independent sets.^[ref][ref]

Molecular evidence provides a different test. The Psychiatric Genomics Consortium's 2014 schizophrenia study identified associations spanning 108 loci in a large multi-stage genome-wide analysis. Many common variants contribute small effects; an associated locus is not automatically one causal gene or a known mechanism. Population stratification, linkage disequilibrium, case ascertainment and sample overlap still require control. A genetic risk score can predict risk differences in independent data while remaining far from a deterministic diagnosis or a transportable measure of one person's psychological resilience.^[ref]

Psychological resilience needs additional definition because favorable outcomes without adversity do not establish psychological stress resistance. Ananda B. Amstadter and colleagues studied 7,500 adult twins at two assessments, modeling internalizing symptoms relative to cumulative stressful events. Their regression residual-based phenotype had estimated heritability around $31\%$ at each wave; longitudinal modeling that accounted for measurement error and occasion-specific influences gave a larger latent estimate, around $50\%$. This supports both inherited and environmental contributions to that operationalization, not a universal percentage for every meaning of psychological resilience.^[ref]

The shift in estimates is conceptually informative. Independent measurement error adds to observed variance without adding the corresponding genetic signal. In a simple measurement model, if $V_G$ is genetic variance, $V_T$ true-score variance and $V_{ϵ}$ independent error variance, thenRemoving noise can therefore raise estimated heritability without changing anyone's genes. This illustration is not a reconstruction of the study's full model: occasion-specific effects and longitudinal assumptions also matter, so $31/50$ should not be reported as an independently established measurement reliability coefficient.

A regression residual phenotype also inherits assumptions from its construction. If adversity is undermeasured or a prediction model is misspecified, the regression residual includes more than protective capacity. Genetic effects on depression or anxiety can appear as genetic effects on low symptom burden after psychological stress, even without a separate buffering mechanism. Demonstrating a psychological resilience-specific effect would require stronger evidence that inherited variation changes the response to comparable exposure, with adequate exposure measurement and explicit competing models.

Gene–environment processes further complicate simple partitioning. Gene-environment correlation occurs when inherited characteristics influence environments encountered or elicited, or when parental characteristics affect both inherited liability and the rearing environment. Genotype-environment interaction instead means that inherited differences have different consequences across environments. Neither can be inferred merely because both genes and psychological stress predict the outcome. Restricting analysis to people with a particular exposure can also create selection bias if exposure is influenced by several causes relevant to symptoms.

Historical candidate-gene findings illustrate the need for stringent evidence. Richard Border and colleagues' large, preregistered analyses did not support widely proposed depression candidate-gene or candidate-gene-by-environment effects. This challenges those specific claims and the power of small discovery studies; it does not demonstrate that all interactions are absent. Replication, correction for multiple testing, ancestry-aware analyses and precise phenotype definitions are essential before a plausible biological story becomes a reliable finding.^[ref]

Finally, high heritability does not mean an outcome cannot be changed. It describes sources of variation under a particular range of environments, not the response to an environment absent from the data. Genetic effects can act through modifiable developmental systems, and external support can benefit people across inherited-risk levels. Predictive accuracy and equity can also deteriorate when scores are transferred to populations unlike the discovery sample.

Genes contribute meaningfully to liability and to particular measured adaptation phenotypes, while evidence for specific protective mechanisms is narrower than evidence for heritability. The strongest account combines family and molecular results with explicit exposure and developmental models, rather than assigning a fixed genetic percentage to an individual or replacing environmental prevention with genetic classification.

A clinical description involving marked disturbances in perception, belief, thought or related functioning, assessed in context. Psychosis is not synonymous with schizophrenia, dangerousness or loss of all capacities.